• Skip to primary navigation
  • Skip to content
  • Skip to primary sidebar
  • Skip to footer

Mr. Free At 33

Dividends • Stocks • Investing

  • My Story
  • Coaching
  • Portfolio
  • Getting Started
  • Media Mentions
  • Contact

Undervalued Dividend Growth Stock Of The Week

July 16, 2017 by Jason Fieber 4 Comments

I uncover a high-quality dividend growth stock that appears to be undervalued each week for Daily Trade Alert, which is a site that focuses on dividend growth investing, stocks, and unique investment opportunities. I’ve been writing for them for years now, and they’re just great over there. Each week, I publish an excerpt of my work, when it’s fresh off the press. That way, you readers are given the opportunity to check it out. The content is totally free. I hope you enjoy!

Famed economist John Maynard Keynes once predicted that people in progressive/developed countries would be working 15-hour workweeks, as abundance and the power of capitalism would end up providing enough basic needs and lifestyle desires at a level of work that was much less than historically necessary.

He had a vision of the future where one of humanity’s biggest challenges would be how to spend so much leisure time.

While Keynes was right about the living standards in progressive/developed countries increasing dramatically over time, allowing for the possibility of dramatically less work, he failed to account for humanity’s never-ending desire for “more”.

In addition, without a massive “buy in” from employers all over the world, the traditional workweek structure remains largely unchanged, which further limits flexibility for the worker class.

Many people are actually working more than ever.

Keep reading…

Image courtesy of: Stuart Miles at FreeDigitalPhotos.net.

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to share on Reddit (Opens in new window)
  • Click to share on Pinterest (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Tumblr (Opens in new window)
  • Click to share on Pocket (Opens in new window)

Filed Under: Dividend Growth Investing

About Jason Fieber

Jason Fieber became financially free at 33 years old by using dividend growth investing to his advantage. Jason has authored two best-selling books: The Dividend Mantra Way and 5 Steps To Retire In 5 Years (also available in paperback).

 

Jason recommends Personal Capital for portfolio management, Mint for budgeting, Schwab for the brokerage account, and Morningstar, Daily Trade Alert, and Motley Fool for stock ideas. This blog is hosted by Bluehost. If you'd like to start your own blog, Jason offers free coaching when you use our Bluehost affiliate link.

 

Jason's writing and/or story has been featured across international media like USA Today, Business Insider, and CNBC.

« A New Measure Of Success
Why I’m Glad I Grew Up Poor »

Reader Interactions

Comments

  1. Super Frugal Duo says

    July 16, 2017 at 11:06 am

    Thanks for covering companies like this in your weekly post. We’re in the early innings of building our dividend portfolio, and we find ourselves drawn to lower-yielding, higher-growth companies at this point. We’ve had our eye on McKesson, as well as AmerisourceBergen and Cardinal Health for a while, so it’s always nice to hear another opinion.

    Reply
    • Jason Fieber says

      July 16, 2017 at 11:12 am

      SFD,

      Yeah, McKesson is definitely on the growth end of the yield-growth spectrum. But if you’re young and have the time, it looks fairly appealing as a long-term idea. I personally prefer CAH in this space, as the balance between yield and growth are more favorable for my needs. Either way, gotta love a good oligopoly. 🙂

      Cheers!

      Reply
  2. turningpointmoney says

    July 16, 2017 at 8:09 pm

    Completely agree that the pharma distributors and PBM’s are out of favor. McKesson has a lot going for it. Investments in international growth, retail pharmacy, growing specialty business, spinoff of MTS with Change Healthcare and not to mention the JV with Walmart. The generic pricing is of concern because of razor thin margins.

    Reply
    • Jason Fieber says

      July 16, 2017 at 8:13 pm

      turningpointmoney,

      Definitely. These names are out of favor, which is why they’ve been popping up recently in the series (CVS was recently featured). John Templeton made a lot of money buying up businesses that were out of favor. Seemed to work pretty well for him. 🙂

      But the razor-thin margins are a bummer. That’s why the fact that there are only a few major players is such a benefit. If you had more competition with those margins, it would be far less attractive.

      Thanks for dropping by!

      Best regards.

      Reply

Join the discussion. Let's have a dialogue. Just please make sure comments are respectful and relevant. Cancel reply

Primary Sidebar

About Me

About Me

Hi. I'm Jason Fieber. I achieved financial independence and retired in my early 30s by using dividend growth investing to my advantage. I cover stock analyses, market news, dividend updates, and the dividend growth investing strategy.

Recommended

My Best-Selling Books

My Best-Selling Books

Let’s Stay In Touch

  • Facebook
  • Twitter

As Seen In

As Seen In

Most Popular

  • Two Big Reasons Behind My Decision To Move Overseas And Become A Dividend Expat 119 comments
  • Financial Freedom Should Be Just One Chapter Of An Otherwise Fantastic Book 110 comments
  • My Recent Experience With Visiting A Hospital In Chiang Mai, Thailand 106 comments
  • Why I Moved Most Of My Assets From Scottrade to Charles Schwab (And Why You May Want To Do The Same) 96 comments
  • It’s Not About The Money: Rent Versus Buy 91 comments

Search

Archives

Categories

Footer

Disclaimer

I’m not a licensed professional of any kind. I’m not a financial advisor, tax professional, or doctor. This site should be viewed for entertainment purposes only. Before you invest any of your money, exercise, or undergo any financial, business, or personal changes at all, please consult an appropriate professional. Unless your investments are FDIC insured, they may decline in value. Any stock transactions and/or analyses I publish should not be considered to be investment recommendations. I am not liable for any losses or suffering experienced by any party.

Privacy Policy

This site does not attempt to collect any personal information whatsoever other than that which is freely shared publicly (through comments), or that which is collected automatically via servers and Google Analytics. I do not sell or voluntarily disclose anyone’s personal information to anyone.

Disclosure

This site is largely supported by way of advertisements. As such, third-party ads may be served up at any time, and I may be paid on your clicking of these ads or your giving of information to third-party representatives. I offer no guarantees as to the accuracy of these ads. These ads may not necessarily reflect or represent my opinions or viewpoints. In addition, I may also have affiliate partnerships with companies whereby I earn a commission if products and/or services are purchased after you click on a link from this site. I only set up affiliate relationships with companies who offer products and/or services that I personally believe in and/or personally use. If I don’t believe in a product and/or service, I don’t endorse it.

Copyright © 2016-2020 Mr. Free At 33. All rights reserved.
sponsored

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

Mr. Free At 33
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognizing you when you return to our website and helping us to understand which sections of the website you find most interesting and useful.

You can adjust all of your cookie settings by navigating the tabs on the left hand side.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.